The Oasis Health Journal · Submitted July 10, 2026 · 5:19 PM ET

Two supplements walked into a dementia trial. One walked out with the better scorecard. That is the short version of a 2025 systematic review in Frontiers in Neurology, which put alpha-GPC and citicoline head-to-head and handed the round to alpha-GPC. Then you reach the methods section, and the plot thickens like a protein shake left in the sun.

Here is what the review actually did. It pooled three randomized controlled trials, 358 older patients with vascular dementia, each treated for 90 days. On the Sandoz Clinical Assessment for Geriatric Patients (a name the field mercifully shortens to SCAG), alpha-GPC beat citicoline on overall clinical condition, with a weighted mean difference of about -3.92 points, where lower is better. It also edged ahead on cognitive function, mood, apathy, sociability, and general physical complaints. Citicoline did not fail. It came in second.

Now the part nobody prints on the label. In all three trials the dose was not a capsule. It was 1,000 mg a day, injected into a muscle. Intramuscular. An actual needle. So the cleanest evidence that alpha-GPC outperforms citicoline comes from a delivery method almost nobody uses to take a supplement. It is a little like proving a car is fast by pushing it off a cliff.

The review is honest about its own soft spots, so we will be too. The three studies were small, old, and open-label, meaning everybody in the room knew what they were getting. They enrolled only vascular dementia, so the results do not automatically carry over to Alzheimer's, and they definitely do not carry over to a healthy 40-year-old hunting for the car keys. And when the same review pooled the memory tests on their own, the gap evaporated. On memory and word fluency, the two were a tie.

Back up to the biology, which is the good part. Both molecules are choline delivery trucks. Your body turns choline into acetylcholine, the neurotransmitter your focus and memory run on, and into phosphatidylcholine, the material your brain cells use to patch their membranes. Alpha-GPC and citicoline (also called CDP-choline) are just two different routes for getting choline across the border and onto that assembly line. Same destination, different passport.

If you want evidence in humans who are not in a dementia ward, citicoline holds the tidier folder. In a randomized controlled trial, 500 mg a day for 12 weeks improved memory in healthy older adults, and a review of citicoline in aging humans landed in the same neighborhood. Those were oral capsules, in ordinary people, which is the exact scenario a supplement shopper lives in. That is why the shelf carries a liposomal citicoline alongside phosphatidylserine and broader brain health formulas, for people building a stack instead of crowning a single champion. Alpha-GPC is not shut out here either: a 2025 study reported a short-term cognitive lift in healthy men from a single dose. The healthy-brain file is thinner, but it is not empty.

Alpha-GPC also keeps a second job that has nothing to do with your memory. It moonlights at the gym. In a small crossover study, 600 mg taken 90 minutes before lifting raised peak bench-press force by roughly 14 percent and set off a large spike in growth hormone. Seven men, one session, so hold the confetti, but it is why alpha-GPC keeps turning up in pre-workout and focus formulas. The same molecule that may nudge a dementia patient's SCAG score is the one gym-goers stir into a shaker. Biology does not read the marketing copy.

Then there is the asterisk nobody stamps on the front of the bottle. A 2021 study followed roughly 12 million Korean adults over 50 and found that alpha-GPC users had a higher 10-year stroke risk, and the risk climbed with the dose. That is an association, not a conviction, and it does not prove the supplement causes strokes. But it is exactly the kind of thing a reasonable person weighs, especially if their blood pressure already keeps its own scorecard.

Worth knowing where these two stand legally, because it is not the same everywhere. In the United States, alpha-GPC and citicoline are both sold as dietary supplements, which means neither is approved to treat or cure anything. In parts of Europe and Asia, choline alphoscerate is a prescription drug for cognitive disorders. Same molecule, very different paperwork depending on your zip code.

The practical read: alpha-GPC owns the head-to-head trophy, but it arrives with an injection-shaped footnote and a stroke question, while citicoline has the better oral, real-people track record and a calmer safety story. Neither is a magic pill, and anything shipped is only as good as what is truly in the capsule. That is the whole reason this shop sources professional-grade choline fresh per order rather than letting bottles age on a shelf. It ships a little slower and lands a little more potent. Worth the wait, when the cargo is your neurotransmitters.

This article is for education only and is not medical advice. Supplements are not a treatment for dementia or any disease. Talk with a qualified clinician before starting alpha-GPC or citicoline, particularly if you have cardiovascular risk factors or take other medications.

Alpha-GPC Beat Citicoline in a 2025 Review. The Fine Print Says the Dose Came From a Syringe.

Sources

Leave a comment

Save 10% off your first purchase

Sources